Next Article in Journal
How to Demonstrate Freedom from African Swine Fever in Wild Boar—Estonia as an Example
Previous Article in Journal
SARS-CoV-2: An Update on Potential Antivirals in Light of SARS-CoV Antiviral Drug Discoveries
Open AccessArticle

Characterization of Physicians That Might Be Reluctant to Propose HIV Cure-Related Clinical Trials with Treatment Interruption to Their Patients? The ANRS-APSEC Study

1
Aix Marseille University, INSERM, IRD, SESSTIM, Sciences Economiques & Sociales de la Santé & Traitement de l’Information Médicale, 13005 Marseille, France
2
INSERM, U1018, Université Paris-Sud 11, AP-HP, Hôpital de Bicêtre, Département D’épidémiologie, 94270 Le Kremlin-Bicêtre, France
3
GRePS, Lyon 2 Université, 69676 Bron, France
4
INSERM, U955, Equipe 16, Université Paris Est, Faculté de médecine, Vaccine Research Institute, 94000 Créteil, France
5
Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Service de Médecine Interne et Immunologie Clinique, INSERM, U1184, 94270 Le Kremlin-Bicêtre, France
6
Immunology of Viral Infections and Autoimmune Diseases, Université Paris Sud, UMR 1184, 94270 Le Kremlin-Bicêtre, France
7
CEA, DSV/iMETI, IDMIT, 92260 Fontenay-aux-Roses, France
*
Author to whom correspondence should be addressed.
Vaccines 2020, 8(2), 334; https://doi.org/10.3390/vaccines8020334
Received: 13 May 2020 / Revised: 4 June 2020 / Accepted: 17 June 2020 / Published: 23 June 2020
(This article belongs to the Special Issue Therapeutic Vaccination of HIV-infected Patients)
HIV cure-related clinical trials (HCRCT) with analytical antiretroviral treatment interruptions (ATIs) have become unavoidable. However, the limited benefits for participants and the risk of HIV transmission during ATI might negatively impact physicians’ motivations to propose HCRCT to patients. Between October 2016 and March 2017, 164 French HIV physicians were asked about their level of agreement with four viewpoints regarding HCRCT. A reluctance score was derived from their answers and factors associated with reluctance identified. Results showed the highest reluctance to propose HCRCT was among physicians with a less research-orientated professional activity, those not informing themselves about cure trials through scientific literature, and those who participated in trials because their department head asked them. Physicians’ perceptions of the impact of HIV on their patients’ lives were also associated with their motivation to propose HCRCT: those who considered that living with HIV means living with a secret were more motivated, while those worrying about the negative impact on person living with HIV’s professional lives were more reluctant. Our study highlighted the need to design a HCRCT that minimizes constraints for participants and for continuous training programs to help physicians keep up-to-date with recent advances in HIV cure research. View Full-Text
Keywords: HIV cure research; HIV cure-related clinical trials; physicians; viewpoints; analytical treatment interruption studies; principal component analysis; multivariable linear regression HIV cure research; HIV cure-related clinical trials; physicians; viewpoints; analytical treatment interruption studies; principal component analysis; multivariable linear regression
Show Figures

Figure 1

MDPI and ACS Style

Protiere, C.; Fressard, L.; Mora, M.; Meyer, L.; Préau, M.; Suzan-Monti, M.; Lelièvre, J.-D.; Lambotte, O.; Spire, B.; the APSEC Study Group. Characterization of Physicians That Might Be Reluctant to Propose HIV Cure-Related Clinical Trials with Treatment Interruption to Their Patients? The ANRS-APSEC Study. Vaccines 2020, 8, 334.

Show more citation formats Show less citations formats
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

1
Search more from Scilit
 
Search
Back to TopTop